Floatz Rating
B62/100
Confidence
Indicative
Sponsor
BioLite, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02802423CT.gov Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. | — | Not Yet Recruiting | — | — | — |
NCT07217990CT.gov Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07017673CT.gov Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06769425CT.gov HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05929768CT.gov Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05714553CT.gov NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
NCT05475678CT.gov Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT05645380CT.gov Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | — | Active Not Recruiting | — | — | — |
NCT04947189CT.gov Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT05076760CT.gov MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | — | Recruiting | — | — | — |
Show 13 more trialsShow fewer
NCT06618014CT.gov Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) | — | Active Not Recruiting | — | — | — |
NCT05088057CT.gov Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer | — | Unknown | — | — | — |
NCT05007106CT.gov MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | — | Completed | — | — | — |
NCT04895709CT.gov A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04095689CT.gov Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT04582955CT.gov Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy | — | Unknown | — | — | — |
NCT03218826CT.gov PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT03639948CT.gov Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer | — | Unknown | — | — | — |
NCT03671044CT.gov A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | — | Recruiting | — | — | — |
NCT02834403CT.gov L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients | — | Completed | — | — | — |
NCT02685657CT.gov Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | — | Unknown | — | — | — |
NCT01216111CT.gov Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) | — | Completed | — | — | — |
NCT01216124CT.gov Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Triple-Negative Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | BioLite, Inc. | P3 | B · 62 |
| Carboplatin | M.D. Anderson Cancer Center | P4 | BB |
| Capivasertib | AstraZeneca | P3 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Veliparib | National Cancer Institute (NCI) | P3 | BB |
| Enzalutamide | Nuvation Bio Inc. | P2 | BB |
| Atezolizumab | European Institute of Oncology | P3 | BB |
| Famitinib | Fudan University | P3 | BB |
| Epirubicin | M.D. Anderson Cancer Center | P4 | BB |
+42 more in the Triple-Negative Breast Carcinoma cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Triple-Negative Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-triple-negative-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →